United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292
Debt
Debt-to-Equity Ratio0.10
Current Ratio4.64
Quick Ratio4.35
Price-To-Earnings
Trailing P/E Ratio11.32
Forward P/E Ratio8.59
P/E Growth29.3
Sales & Book Value
Annual Sales$1.73 billion
Price / Sales3.12
Cash Flow$11.7567 per share
Price / Cash10.52
Book Value$48.64 per share
Price / Book2.54
Profitability
EPS (Most Recent Fiscal Year)$10.89
Net Income$417.90 million
Net Margins40.87%
Return on Equity34.42%
Return on Assets25.95%
Miscellaneous
Employees800
Outstanding Shares43,560,000
Market Cap$5.51 billion
United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions
What is United Therapeutics' stock symbol?
United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."
How will United Therapeutics' stock buyback program work?
United Therapeutics declared that its board has authorized a stock repurchase program on Sunday, June 4th 2017, which permits the company to buyback $250,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 4.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board of directors believes its shares are undervalued.
How were United Therapeutics' earnings last quarter?
United Therapeutics Co. (NASDAQ:UTHR) announced its quarterly earnings data on Wednesday, August, 1st. The biotechnology company reported $3.98 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.57 by $1.41. The biotechnology company earned $444.50 million during the quarter, compared to analyst estimates of $368.63 million. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The business's revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the company posted $4.37 EPS. View United Therapeutics' Earnings History.
When is United Therapeutics' next earnings date?
What price target have analysts set for UTHR?
6 equities research analysts have issued 12 month price targets for United Therapeutics' stock. Their forecasts range from $95.00 to $253.00. On average, they expect United Therapeutics' stock price to reach $140.8333 in the next twelve months. This suggests a possible upside of 14.0% from the stock's current price. View Analyst Price Targets for United Therapeutics.
What is the consensus analysts' recommendation for United Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for United Therapeutics.
What are Wall Street analysts saying about United Therapeutics stock?
Here are some recent quotes from research analysts about United Therapeutics stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to achievement of target price. Our price target of $95/share is based on an equally weighted composite of (a) $102/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $6.03 discounted back to and (b) an NPV of $89/share, discount rate 12.5%, growth rate -2%." (8/2/2018)
- 2. According to Zacks Investment Research, "United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. The company has many phase III programs in the fields of cardiopulmonary diseases and oncology. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Several data read-outs and regulatory updates are expected in 2018. The latest deal to merge with SteadyMed will add SteadyMed’s drug device pipeline product Trevyent to its portfolio, which could have posed competition to RemoSynch. However, competition in the PAH market is increasing, which is a concern. We believe the company needs to use cash suitably to deal with potential generic competition for two of its biggest products - Remodulin and Adcirca - by mid-2018. United Therapeutics’ shares have also underperformed the industry this year so far." (7/15/2018)
Who are some of United Therapeutics' key competitors?
Some companies that are related to United Therapeutics include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX) and Bausch Health Companies (BHC).
Who are United Therapeutics' key executives?
United Therapeutics' management team includes the folowing people:
- Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 63)
- Mr. Michael I. Benkowitz, Pres & COO (Age 46)
- Mr. James C. Edgemond, CFO & Treasurer (Age 50)
- Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54)
- Kevin Gray, Sr. VP of Strategic Operations & Logistics
Has United Therapeutics been receiving favorable news coverage?
News articles about UTHR stock have trended somewhat positive on Wednesday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. United Therapeutics earned a media and rumor sentiment score of 0.10 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.54 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for United Therapeutics.
Who are United Therapeutics' major shareholders?
United Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.54%), FMR LLC (8.08%), Renaissance Technologies LLC (3.57%), Acadian Asset Management LLC (2.63%), Dimensional Fund Advisors LP (2.27%) and First Trust Advisors LP (1.57%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.
Which major investors are selling United Therapeutics stock?
UTHR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bridgewater Associates LP, Los Angeles Capital Management & Equity Research Inc., Mackay Shields LLC, Russell Investments Group Ltd., Wedge Capital Management L L P NC, Senzar Asset Management LLC and Point72 Asset Management L.P.. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Judy D Olian, Martine A Rothblatt and Raymond Dwek. View Insider Buying and Selling for United Therapeutics.
Which major investors are buying United Therapeutics stock?
UTHR stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, First Trust Advisors LP, BlackRock Inc., Greylin Investment Mangement Inc., Bank of Montreal Can, Alps Advisors Inc., BNP Paribas Arbitrage SA and United Services Automobile Association. View Insider Buying and Selling for United Therapeutics.
How do I buy shares of United Therapeutics?
Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is United Therapeutics' stock price today?
One share of UTHR stock can currently be purchased for approximately $123.51.
How big of a company is United Therapeutics?
United Therapeutics has a market capitalization of $5.51 billion and generates $1.73 billion in revenue each year. The biotechnology company earns $417.90 million in net income (profit) each year or $10.89 on an earnings per share basis. United Therapeutics employs 800 workers across the globe.
How can I contact United Therapeutics?
United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]
MarketBeat Community Rating for United Therapeutics (NASDAQ UTHR)
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
